Merck Serono Acquires Multiple Sclerosis Drug; Nixon Peabody Legal Team Advises on Deal
October 14, 2011 // Franchising.com // Boston, MA. Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has acquired the worldwide exclusive development and commercialization rights to PI-2301, an experimental drug for multiple sclerosis.
PI-2301 is a second-generation peptide copolymer that is thought to enhance the regulatory response of the immune system and dampen immune responses that drive autoimmune diseases such as multiple sclerosis. Merck will evaluate the product for autoimmune diseases including multiple sclerosis. The drug was originally developed by Peptimmune, the Cambridge, MA–based peptide therapeutics firm.
Nixon Peabody LLP served as Merck Serono’s legal counsel. The team was led by global business & transactions and life sciences partner Chris Keefe and bankruptcy & financial restructuring practice group leader Victor Milione. Patents group partner Mark FitzGerald also worked on the deal.